A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial
BMC Cancer (2012) - Comments
pubmed: 22439666  doi: 10.1186/1471-2407-12-108  issn: 1471-2407 

Anne Katrin Berger, Carl Von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger